Stephen Hanauer

21PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersToxicology (incl. clinical toxicology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 31, 2026
End User Needs and Perspectives for a Digital Opioid Safety Tool in Adolescents and Young Adults With Inflammatory Bowel Disease: A Qualitative Human-Centered Design Study.

|Jul 21, 2026
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.

|Jun 29, 2026
The association between 6-thioguanine nucleotide levels, adalimumab exposure, immune response, and drug clearance.

|May 13, 2026
Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease.

|Apr 15, 2026
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

|Mar 18, 2026
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.

Marla C Dubinsky, Stefan Schreiber, Andres J Yarur

Pageof 4

Frequent Collaborators

6 joint publications

Jean-Frederic Colombel

6 joint publications

Silvio Danese

4 joint publications

Bruce E Sands

4 joint publications

Stefan Schreiber